Pirkanmaan hyvinvointialue

Evopcinumnj 2i Txdewges 3tphgh Fxhrhww

Nervous System Diseases

The Pirkanmaan hyvinvointialue research center in Tampere concentrates its clinical programs on Nervous System Diseases, primarily exploring treatments for multiple sclerosis.

Relapsing multiple sclerosis
Progressive multiple sclerosis
Long‑term safety and tolerability evaluation
Investigation of novel BTK inhibitors
Patient‑focused outcome measures

Across five active trials, a team of 74 investigators is assessing the safety profile of new therapies such as tolebrutinib to expand treatment options for individuals living with multiple sclerosis. The work aims to enhance long‑term disease management and improve quality of life for patients.

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Recruiting

3 1 1
Investigated Drugs:
+6
Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

Recruiting

3 1 1
Investigated Drugs:
- [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
- Imatinib Mesilate
+7
Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Recruiting

3 1 1 1
Investigated Drugs:
- HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
- Bevacizumab
+6
Phase 1/2 Study Evaluating Safety and Activity of GSK5926371 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting

1 1 1
Investigated Diseases:
- Non-Hodgkin’s lymphoma
Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Recruiting

3 1
Investigated Diseases:
- Interstitial lung disease
Investigated Drugs:
+6
Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Recruiting

3 1 1 1
Investigated Drugs:
- Cabozantinib
+2
Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Recruiting

4 1
Investigated Diseases:
- Chronic obstructive pulmonary disease
Investigated Drugs:
- LUNSEKIMIG
+7
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Recruiting

3 1
Investigated Diseases:
- Primary progressive multiple sclerosis
+14
Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Recruiting

3 1 1 1
Investigated Drugs:
- Pembrolizumab
+10
Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Recruiting

3 1 1 1
Investigated Diseases:
- Neuroendocrine carcinoma
Investigated Drugs:
+8